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Table. Distribution of procedures
Age, years
Thoracic Thoracoabdominal Aortoiliac Subclavian/carotid/vertebral Others
Open Endo Open Endo Open Endo Open Endo Open Endo
Marfans (n ¼ 42) 37.4 6 15.7 69 11 16 3 9 8 5 1 12 5
EDSa (n ¼ 15) 42.3 6 15.9 14 3 3 2 3 4 0 1 2 2
LDS (n ¼ 6) 35.8 6 15.5 9 0 3 0 1 2 4 3 1 1
Total - 92 14 22 5 13 14 9 5 15 8
aOne patient had both EDS & LDS, and underwent 2 open thoracic and 1 endovascular subclavian intervention
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rapidly expanding, allowing for categorization of previously
undiagnosed patients. Endovascular options are viable and
useful when there is acceptable vascular morphology and
the procedure is planned properly, potentially in a hybrid
modality.
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Objectives: The purpose of this study was to catego-
rize patients referred to a specialized thoracic outlet
syndrome (TOS) practice.
Methods: Demographic and clinical data on all
patients who were referred for TOS between 2006
and 2010 were retrospectively reviewed from a prospec-
tively maintained, IRB approved database and patient
records.
Results: Between 2006-2010, 621 patients were
referred for TOS (433F/188M; mean age, 39 years [range,
10-87]). 571 (92%) were diagnosed with TOS-421 (74%)
neurogenic, 126 (22%) venous and 24 (4%) arterial. Of the
525 physician referrals, 478 (91%) had TOS and of the 93
self referrals, 90 (97%) had TOS.
The 421 patients with neurogenic TOS (NTOS)
(304F/117M) had symptoms on average for 56 months
(range, 1-516). 271 (64%) were initially treated with
TOS speciﬁc physical therapy (PT) and 100 (37%)
improved. 178 (42%) underwent a lidocaine block and
145 (81%) had a positive block. 74 (18%) patients under-
went botox injections-44 (60%) were positive and the
average number of botox injections was 1.3. 140 (33%)
underwent First Rib Resection and Scalenectomy (FRRS)
and 128 (91%) improved. Of patients undergoing FRRS,
92 (66%) had a lidocaine block, 82 (89%) of which were
positive. Of patients with a positive lidocaine block, 74(90%) improved following FRRS. Of patients undergoing
FRRS, 31 (22%) underwent botox injections, 15 (48%)
of which were positive. Of patients with a positive lidocaine
block, 14 (93%) improved following FRRS. Average length
of time between initial visit and operation was 6.4 months
(Range 2 weeks-34 months) and average follow up was 13
months (Range 1 week-49 months).
Conclusions:
1. Both referring physicians and patients are very
accurate in their preliminary diagnosis of TOS-
neurogenic, venous, or arterial.
2. In a specialized TOS practice, 2/3 of patients are
sent to TOS speciﬁc PT and 1/3 improve from
that alone.
3. 1/3 of patients referred for NTOS eventually
undergo FRRS with a 91% success rate.
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Objectives: Dietary intake of n-3 PUFAs has been
associated with cardiovascular disease, but the relationship
to PAD is unclear. PAD patients have an increased burden
of systemic inﬂammation. In a cross-sectional cohort study,
we evaluated the relationship between n-3 PUFAs content
of red blood cells (omega-3 index) and biomarkers of
inﬂammation.
Methods: This was a prospective cohort study of
patients (n ¼ 83) presenting to vascular surgery clinic for
evaluation of PAD. We used linear regression to evaluate
the independent association between the omega-3 index
(gas chromatography) and inﬂammation (hsCRP, IL-6,
TNF-a and ICAM-1; ELISA kits).
Results: 70 patients had PAD while 13 were found to
have a normal ankle-brachial index (ABI). Mean (6 SD)
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omega-3 index decreased across AHA hsCRP categories
(Fig; P ¼ .04). One percentage point decrease in the
omega-3 index was associated with increases in CRP (14%,
95% CI 0; 25; P ¼ .04), IL6 (8%; 95% CI, 1-15; P ¼ .02)
and possibly ICAM-1 (4%; 95% CI, 1-12; P ¼ .13), but
not TNF-a. After adjusting for age, race, HDL, smoking
status, ABI and the body-mass index, the omega-3 index
remained signiﬁcantly (negatively) associated with systemic
inﬂammation as measured by hsCRP in a male population
at risk or suffering from PAD (P ¼ .05).
Conclusions: In a contemporary cohort of patients
with PAD, the omega-3 index was negatively associated
with biomarkers of inﬂammation. Our ﬁndings suggest
a rationale for future studies of dietary manipulation of
omega-3 index to reduce inﬂammation in patients with
PAD.
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Nothing to disclose; E. Vittinghoff: Nothing to disclose.Fig. This ﬁgure displays FGRC in extremity PTFE grafts was
15.4%/8.05 yr and 76.9%/8.05 yr for extremity autologous vein
grafts (P ¼ .044).
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Objectives: Reconstruction of vascular injury often
requires autologous vein (AV) or expanded polytetra-
ﬂuoroethylene (ePTFE) conduit. To date the durabilityof ePTFE as an adjunct to vascular repair in the combat
setting is unknown. The objective of this study is to
compare the long-term effectiveness of ePTFE to AV in
repair of wartime vascular injury.
Methods: US service personnel undergoing vascular
repair (2002-2012) were identiﬁed. Patients in whom
ePTFE was used as an interposition conduit (n ¼ 25)
were matched to those who received AV (n ¼ 24). Injury
and operative factors were assessed and freedom from
graft-related complication quantiﬁed using Kaplan-Meier
log-rank test.
Results: Follow up for the ePTFE and AV groups was
71 and 62 months respectively. There was no difference
between ePTFE and AV groups in age, injury severity or,
mangled extremity severity scores. In the overall cohort
there was an apparent but not signiﬁcantly greater freedom
from graft related complication for AV compared to
ePTFE (65.4% vs 17.1%; P ¼ .13). In the extremity posi-
tion AV demonstrated greater freedom from graft related
complication than ePTFE (Fig). In the carotid/subcla-
vian/axillary positions ePTFE performed equally well as
AV (P ¼ .9).
Conclusions: Autologous vein is a more durable
conduit than ePTFE in repair of wartime extremity vascular
injury while ePTFE is effective and durable in the carotid,
subclavian, and axillary locations.
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